Observational studyActa obstetricia et gynecologica Scandinavica2022
Maternal alloimmune antibodies against HPA and HLA class I antigens are associated with reduced birthweight among healthy neonates delivered by Chinese women.
Observational study in Acta obstetricia et gynecologica Scandinavica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
- Maternal alloimmune antibodies against HPA and HLA class I antigens are associated with reduced birthweight among healthy neonates delivered by Chinese women.Acta obstetricia et gynecologica Scandinavica · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt is well known that HPA-1a antibodies lead to fetal and neonatal alloimmune thrombocytopenia (FNAIT), and an association with reduced birthweight in boys has been reported. Although it remains unclear whether HLA antibodies cause FNAIT, an association between HLA class I antibodies and reduced birthweight in FNAIT neonates has been observed. The aim of this study was to investigate the incidence of platelet antibodies among Chinese women and the impact of maternal alloimmune antibodies on birthweight among healthy neonates. MATERIAL AND
methodsIn this retrospective observational cohort study, platelet antibody screening was performed among women hospitalized for delivery from March 2019 to November 2020. A portion of each serum sample was used to distinguish HLA class I antibodies from HPA antibodies. Based on neonatal sex, gestational age and maternal age, platelet antibody-negative women who were hospitalized for delivery during the same period were randomly selected as reference groups at a 1:1 ratio for comparisons of the birthweights of healthy neonates delivered by women who were positive or negative for platelet antibodies.
resultsAmong 15 156 women, 1008 (6.7%) were positive for platelet antibodies; the incidences of positive platelet antibody were 1.2%, 1.9%, 1.6% and 2.0% among women with 1, 2, 3 and >3 pregnancies, respectively. Among 787 platelet antibody-positive serum samples available for further analysis, 548 (69.6%) were positive for HLA class I antibodies bound to platelets, and 239 (30.4%) were positive for HPA antibodies. The average birthweight of healthy neonates delivered by women who were positive for platelet antibodies, HLA class I antibodies or HPA antibodies was 161-483 g lower than that of neonates delivered by women who were negative for these antibodies (P < 0.001). Regarding birthweight reduction, there was no significant difference among women who were positive for these antibodies or between boys and girls (P > 0.05).
conclusionsThis study is the first to report that maternal HPA and HLA class I antibodies are associated with reduced birthweight among healthy neonates delivered by Chinese women. This finding provides information for the study of the effect of maternal alloimmune antibodies on fetal development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.